110 related articles for article (PubMed ID: 29713749)
1. A rare case of an acquired factor V inhibitor in a patient with myelodysplastic syndrome during azacitidine treatment.
Fujita Y; Nakazato T; Ito C; Masuda K; Osada Y; Aisa Y; Mori T
Ann Hematol; 2018 Oct; 97(10):2009-2010. PubMed ID: 29713749
[No Abstract] [Full Text] [Related]
2. An acquired factor V inhibitor associated with defective factor V function, storage and binding to multimerin 1.
Jeimy SB; Krakow EF; Fuller N; Tasneem S; Hayward CP
J Thromb Haemost; 2008 Feb; 6(2):395-7. PubMed ID: 18047547
[No Abstract] [Full Text] [Related]
3. Acquired factor V inhibitor developing in a patient with esophageal squamous cell carcinoma.
Ahmadinejad M; Roushan N
Blood Coagul Fibrinolysis; 2013 Jan; 24(1):97-9. PubMed ID: 23080366
[TBL] [Abstract][Full Text] [Related]
4. Successful management of transcatheter aortic valve implantation by platelet transfusions in a nonagenarian patient with severe autoimmune factor V deficiency.
Mouton C; Leroux L; Bonnet G; Seguy B; Lafargue A; Baulier G; Castet S; Fiore M
Ann Hematol; 2019 Aug; 98(8):1991-1992. PubMed ID: 30830247
[No Abstract] [Full Text] [Related]
5. [Effective treatment of myelodysplastic syndromes-refractory anemia with excess blasts type II by decitabine: a case report].
Bao L; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):573. PubMed ID: 22967422
[No Abstract] [Full Text] [Related]
6. Multimodality therapy of an acquired factor V inhibitor.
Fu YX; Kaufman R; Rudolph AE; Collum SE; Blinder MA
Am J Hematol; 1996 Apr; 51(4):315-8. PubMed ID: 8602633
[TBL] [Abstract][Full Text] [Related]
7. [Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
Fernández-Sojo J; Vives S; Oliveras Vilà T; Ribera JM
Med Clin (Barc); 2014 Jul; 143(1):43-4. PubMed ID: 24183124
[No Abstract] [Full Text] [Related]
8. Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
Salim O; Toptas T; Avsar E; Yucel OK; Ozturk E; Ferhanoglu B; Geduk A; Mehtap O; Tombak A; Tiftik EN; Deveci B; Kurtoglu E; Kara O; Atagunduz IK; Tuglular TF; Undar L
Leuk Res; 2016 Jun; 45():82-9. PubMed ID: 27107658
[TBL] [Abstract][Full Text] [Related]
9. An Unexpected Innocent Complication Associated with Azacitidine Treatment of Myelodysplastic Syndrome: Erythema Annulare Centrifugum.
Turan Erkek E; Kalayoğlu Beşışık S
Turk J Haematol; 2016 Mar; 33(1):81-2. PubMed ID: 27020727
[No Abstract] [Full Text] [Related]
10. Acquired factor V inhibitor after antibiotic treatment in a patient with pneumonia: a case report.
Taniwaki M; Katsutani S; Yamasaki M; Kawamoto K; Funaishi K; Matsumoto Y; Matsumoto N; Ohashi N; Hattori N
Ann Hematol; 2019 Aug; 98(8):1989-1990. PubMed ID: 30747247
[No Abstract] [Full Text] [Related]
11. Systemic mastocytosis emerging after azacitidine treatment of refractory anaemia with excess blasts type 2.
Xu Z; Shier L; Sabloff M; McCurdy A; Sheppard D; Bredeson C
Br J Haematol; 2014 Oct; 167(2):147. PubMed ID: 25040664
[No Abstract] [Full Text] [Related]
12. Acquired factor V deficiency in a patient with a urinary tract infection presenting with haematuria followed by multiple haemorrhages with an extremely low level of factor V inhibitor: a case report and review of the literature.
Wang X; Qin X; Yu Y; Wang R; Liu X; Ji M; Zhou M; Chen C
Blood Coagul Fibrinolysis; 2017 Jun; 28(4):334-341. PubMed ID: 27428013
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment with rituximab in a patient with an acquired factor V inhibitor.
Lebrun A; Leroy-Matheron C; Arlet JB; Bartolucci P; Michel M
Am J Hematol; 2008 Feb; 83(2):163-4. PubMed ID: 17849464
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness and safety of 5-azacitidine in three patients with myelodysplastic syndromes].
Garzás-Martín de Almagro MC; Gago Sánchez AI; Cuevas Asencio I; Reyes Malia M
Farm Hosp; 2010; 34(4):204-8. PubMed ID: 20185350
[TBL] [Abstract][Full Text] [Related]
15. High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors.
Bayani N; Rugina M; Haddad-Vergnes L; Lelong F
Am J Hematol; 2002 Sep; 71(1):33-6. PubMed ID: 12221671
[TBL] [Abstract][Full Text] [Related]
16. Acquired factor V inhibitor in systemic vasculitis.
Ciang CO; Leung MH
Int J Rheum Dis; 2012 Apr; 15(2):e19-22. PubMed ID: 22462428
[No Abstract] [Full Text] [Related]
17. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C
Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352
[TBL] [Abstract][Full Text] [Related]
18. Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.
Möller I; Blum S; Gattermann N; Haas R; Habersang K; Germing U; Kuendgen A
Ann Hematol; 2009 Nov; 88(11):1141-4. PubMed ID: 19290525
[No Abstract] [Full Text] [Related]
19. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.
Sekeres MA; O'Keefe C; List AF; Paulic K; Afable M; Englehaupt R; Maciejewski JP
Am J Hematol; 2011 Jan; 86(1):102-3. PubMed ID: 21080340
[TBL] [Abstract][Full Text] [Related]
20. [Antiplatelet antibodies in a patient with refractory anemia with excess of blasts].
Torreiro EG; Batlle J; Cachaza FF; Lago CF
Sangre (Barc); 1991 Oct; 36(5):435. PubMed ID: 1816643
[No Abstract] [Full Text] [Related]
[Next] [New Search]
